The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2023A Phase I Retest Study of Imaging Tracer MODAG-005 in Parkinson’s Disease, Multiple System Atrophy and Healthy Volunteers
Study Rationale: In many neurodegenerative disorders, including Parkinson’s disease (PD) and (MSA), the protein alpha-synuclein is structurally altered and forms aggregates in the brain. These...
-
Research Grant, 2023Preclinical Development of Disease-modifying Therapies for Treating Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by the hallmark accumulation of toxic clumps of alpha-synuclein, particularly a modified form of the protein called pS129. Acurex has...
-
Translational Pipeline Program, 2023Using Sleep Modulation to Enhance the Brain’s Waste Clearance Mechanisms as an Approach to Limiting the Progression of Parkinson’s Disease
Study Rationale: Recent studies have demonstrated that the brains of people with Parkinson’s disease (PD) show a buildup of toxic proteins that is due to an impairment in the brain’s waste clearance...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2023Evaluating Polyamines as Biomarkers for Parkinson’s Disease
Study Rationale: One of genes associated with Parkinson’s disease (PD), ATP13A2, regulates the levels of polyamines in the lysosome, an acidic compartment of the cell. Polyamines are neuroprotective...
-
Biomarkers to Support Therapeutic Trials Program, 2023Developing a Novel Platform for Patient Selection and Disease Tracking Using Super-resolution Microscopy and AI
Study Rationale: The ability to track alpha-synuclein pathology in tissues outside the brain would facilitate accurate diagnosis of Parkinson's disease (PD), enable inclusion of individuals with alpha...
-
Translational Pipeline Program, 2023Exploring the Use of Molecules that Stabilize the Interaction between LRRK2 Kinase and the 14-3-3 Adapter Protein as a Neuroprotective Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is associated with activating mutations in a protein kinase called LRRK2. In previous studies, we found that regulating LRRK2’s chemical modification by...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.